No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Tumor Lysis Syndrome (TLS) is a metabolic disorder that can occur in cancer patients as a result of the rapid breakdown of tumor cells. TLS is characterized by the release of large amounts of intracellular contents, such as potassium, phosphate, and uric acid, into the bloodstream. This can lead to electrolyte imbalances, kidney failure, and other serious complications. To prevent TLS, oncology drugs are used to reduce the number of tumor cells and prevent the release of intracellular contents.
The TLS drugs market is a subset of the oncology drugs market. It includes drugs that are used to reduce the risk of TLS in cancer patients. These drugs are typically administered prior to chemotherapy or radiation therapy to reduce the number of tumor cells and prevent the release of intracellular contents.
Some companies in the TLS drugs market include Pfizer, Novartis, Merck, and Bristol-Myers Squibb. Show Less Read more
